Pure Global
NCT06242067

Second-line Treatment of Metastatic Colorectal Cancer

Irinotecan in Combination With Trifluridine-tipiracil and Bevacizumab in Pre-treated Metastatic Colorectal Cancer
Qilu Hospital of Shandong University·Phase 2·ClinicalTrials.gov·drugRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Metastatic Colorectal Cancer
Drug/Device/Intervention
Trifluridine/tipiracil
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
Qilu Hospital of Shandong University
Location
Jinan, China
Timeline & enrollment
Phase
Phase 2
Start date
Apr 23, 2023
End date
Dec 01, 2026
Enrollment
50 participants
Primary outcome

progression-free survival(PFS)

Summary

The goal of this multicenter, single-arm, observational cohort study is to investigate the
 efficacy and safety of irinotecan in combination with trifluridine-tipiracil and bevacizumab
 in colorectal cancer with prior oxaliplatin and fluoropyrimidine-based chemotherapy
 (including 5-FU/capecitabine/S-1) exposure in the metastatic setting or within 12 months of
 recurrence.

ICD-10 classifications
Malignant neoplasm of colonMalignant neoplasm: Colon, unspecifiedMalignant neoplasm: Descending colonMalignant neoplasm: Ascending colonMalignant neoplasm: Overlapping lesion of colon
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06242067
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06242067 through Pure Global AI's free database. This Phase 2 trial is sponsored by Qilu Hospital of Shandong University and is currently Recruiting. The study focuses on Metastatic Colorectal Cancer. Target enrollment is 50 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.